determination against only four (4) of the Defaulted Respondents: Darui Development, Dongguan Electronic, Shenzhen Rich Hao, and Shenzhen Saen. Specifically, OUII argued Complainants did not sufficiently connect the importation, sale, or sale after importation of certain of the Accused Products to the Defaulted Respondents. Otherwise, OUII stated it generally supports a finding that Complainants have satisfied the economic prong of the domestic industry requirement under Section 337(a)(3)(A) and (B) (19 U.S.C. 1337(a)(3)(A), (B)) and also supports Complainants' remedy requests.

On March 25, 2022, the presiding administrative law judge (''ALJ'') issued an initial determination (Order No. 15) granting in part and denying in part Complainants' motion for summary determination. The ID finds that Complainants have shown by reliable, probative, and substantial evidence that a violation of Section 337 has occurred with respect to the Asserted Patents as to the following four Defaulted Respondents: Darui Development, Dongguan Electronic, Shenzhen Rich Hao, and Shenzhen Saen. The ID finds that no violation has been established as to any other respondent. The ALJ's recommended determination on remedy and bonding (''RD'') recommends issuance of a GEO with respect to the asserted patents. The RD does not recommend issuance of any cease and desist order.

On April 6, 2022, OUII petitioned for review of certain aspects of the subject ID. No other petitions or responses to petitions were filed.

On May 11, 2022, the Commission determined to review the subject ID in part. *See* 87 FR 29879–80 (May 17, 2022). Specifically, the Commission determined to review the ID's finding regarding the economic prong of the domestic industry requirement and requested briefing. *Id.* at 29880. In addition, the Commission determined to review in part the ID for the limited purpose of making certain corrections in the ID. *Id.* The Commission also requested written submissions on remedy, the public interest, and bonding. *Id.*

On May 25, 2022, Complainants and OUII filed their opening written submissions on the issue under review and on remedy, the public interest, and bonding. On June 1, 2022, OUII filed a reply remedy submission. No other submissions were received by the Commission.

Having reviewed the submissions filed in response to the Commission notice, *see id.,* and the evidentiary record, the Commission has determined to affirm the ID's finding of a violation of Section 337 in this investigation. The Commission has also determined that the appropriate form of relief in this investigation is a GEO prohibiting the unlicensed importation of certain batteries and products containing same that infringe the '868 patent, the '353 patent, and the '944 patent.

The Commission has further determined that the public interest factors enumerated in Subsection (d)(1) (19 U.S.C. 1337(d)(1)) do not preclude issuance of the above-referenced remedial order. Finally, the Commission has determined that a bond in the amount of one hundred (100) percent of the entered value is required to permit temporary importation of the articles in question during the period of Presidential review (19 U.S.C. 1337(j)). The investigation is terminated.

The Commission's order and the record upon which it based its determination were delivered to the President and to the United States Trade Representative on the day of their issuance. The Commission has also notified the Secretary of the Treasury of the order.

The Commission vote for this determination took place on July 25, 2022.

The authority for the Commission's determination is contained in Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: July 25, 2022.

Katherine M. Hiner,

Acting Secretary to the Commission.

[FR Doc. 2022–16262 Filed 7–28–22; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1239]

Certain Gabapentin Immunoassay Kits and Test Strips, Components Thereof, and Methods Therefor; Notice of Commission Determination To Issue a Limited Exclusion Order Against Defaulting Respondent; Termination of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined to issue a limited exclusion order against Kappa City Biotech, SAS of Montlucon, France (''Kappa City''). The Commission has also determined to impose a bond equal to one hundred (100) percent of the entered value of the infringing products imported during the period of Presidential review. The investigation is hereby terminated.

FOR FURTHER INFORMATION CONTACT: Lynde Herzbach, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–3228. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.* For help accessing EDIS, please email *EDIS3Help@usitc.gov.* General information concerning the Commission may also be obtained by accessing its internet server at *https://www.usitc.gov.* Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: On January 25, 2021, the Commission instituted this investigation under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (''section 337''), based on a complaint filed by ARK Diagnostics, Inc. of Fremont, California (''ARK''). *See* 86 FR 6918–19. The complaint, as supplemented, alleges a violation of section 337 based upon the importation into the United States, sale for importation, or sale after importation into the United States of certain gabapentin immunoassay kits and test strips, components thereof, and methods therefor by reason of infringement of certain claims of U.S. Patent Nos. 8,828,665 and 10,203,345. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The notice of investigation names fourteen respondents, including Kappa City; Healgen Scientific, LLC of Houston, Texas; 12PanelMedical, Inc. of Sarasota, Florida; Acro Biotech, Inc. of Rancho Cucamonga, California; AlcoPro, Inc. of Knoxville, Tennessee; American Screening, LLC of Shreveport, Louisiana; Chemtron Biotech Co., Ltd. of San Diego, California; Confirm Biosciences, Inc. of San Diego, California; Hangzhou All Test Biotech Co., Ltd. of Hangzhou, China; Mercedes Medical, LLC of Lakewood Ranch, Florida; TransMed Co., LLC of Alpharetta, Georgia; Transmetron, Inc. of Salt Lake City, Utah; Zhejiang Orient Gene Biotech Co., Ltd. of Huzhou, China; and Shanghai Chemtron Biotech

Co., Ltd. of Shanghai, China (''Shanghai Chemtron''). *See id.* The complaint and notice of investigation were later amended to add two respondents, 12Panel Now, Inc. and Hospital Connect, Inc., both of Boynton Beach, Florida. Order No. 8 (March 9, 2021), *unreviewed by* 86 FR 16640–41 (March 30, 2021).

The Commission previously terminated six respondents based on consent orders. Order Nos. 11 and 12 (Mar. 31, 2021), *unreviewed by* Comm'n Notice (Apr. 15, 2021) (TransMed Co., LLC, 12PanelMedical, Inc., 12Panel Now, Inc., and Hospital Connect, Inc.); Order No. 14 (April 9, 2021), *unreviewed by* Comm'n Notice (Apr. 22, 2021) (Mercedes Medical, LLC); Order No. 15 (April 12, 2021), *unreviewed by* Comm'n Notice (May 12, 2021) (Transmetron Inc.). The Commission also previously terminated four respondents based on settlement agreements. Order No. 13 (Apr. 5, 2021), *unreviewed by* Comm'n Notice (Apr. 19, 2021) (Confirm Biosciences, Inc.); Order No. 17 (May 5, 2021), *unreviewed by* Comm'n Notice (May 18, 2021) (AlcoPro, Inc.); Order No. 18 (May 20, 2021), *unreviewed by* Comm'n Notice (June 21, 2021) (American Screening, LLC); Order No. 29 (Jan. 31, 2022), *unreviewed by* 87 FR 11096–98 (Feb. 28, 2022) (Shanghai Chemtron). The Commission also terminated five respondents based on partial withdrawal of the complaint. Order No. 20 (June 4, 2021), *unreviewed by* Comm'n Notice (June 28, 2021) (Chemtron Biotech, Inc.); Order No. 21 (June 14, 2021), *unreviewed by* Comm'n Notice (July 1, 2021) (Hangzhou AllTest Biotech Co., Ltd.; Acro Biotech, Inc.; Zhejiang Orient Gene Biotech Co, Ltd.; Healgen Scientific, LLC).

On May 18, 2021, the Commission determined not to review an initial determination (Order No. 16) finding Kappa City in default. Order No. 16 (Apr. 30, 2021), *unreviewed by* Comm'n Notice (May 18, 2021).

On December 7, 2021, ARK filed a declaration seeking immediate entry of a limited exclusion order and cease and desist order against Kappa City.

On February 22, 2022, the Commission determined not to review an initial determination granting a motion to terminate Shanghai Chemtron based on settlement. *See* Order No. 29 (Jan. 31, 2022), *unreviewed by* 87 FR 11096–98 (Feb. 28, 2022). The Commission concurrently determined that ARK's declaration was moot given the termination of the final remaining non-defaulting respondent in this investigation. 87 FR at 11097. The Commission also requested briefing on the issues of remedy, bonding, and the public interest. *Id.*

On March 8, 2022, ARK filed the sole response to the Commission's request for briefing. No replies or other submissions were received.

Upon review of the record, including ARK's submission, and in the absence of any response from Kappa City or from other interested persons or government agencies, the Commission has determined to issue a limited exclusion order against Kappa City pursuant to section 337(g)(1). The Commission has determined not to issue a cease and desist order against Kappa City, which is a foreign respondent. *See, e.g., In the Matter of Certain Powered Cover Plates,* Inv. No. 337–TA–1124, Comm'n Op. at 24–28 (July 10, 2020); *Certain Earpiece Devices and Components Thereof,* Inv. No. 337–TA-1121, Comm'n Op. at 42–44 (Nov. 9, 2019); *Certain Electric Skin Care Devices, Brushes and Chargers Therefore, and Kits Containing the Same,* Inv. No. 337–TA–959, Comm'n Op. at 28–33 (Feb. 13, 2017). The Commission has determined that the public interest factors do not preclude issuance of the remedial order. The Commission has further determined to set a bond in the amount of one hundred (100) percent of the entered value of the covered products imported during the period of Presidential review (19 U.S.C. 1337(j)). The Commission's order was delivered to the President and the United States Trade Representative on the day of its issuance. The investigation is hereby terminated.

Commissioners Schmidtlein and Karpel would issue both a limited exclusion order and a cease and desist order against Kappa City pursuant to section 337(g)(1) because all requirements of this provision are met. 19 U.S.C. 1337(g)(1)(A)–(E). Specifically, Kappa City was named in the complaint and was served the complaint and notice of investigation. *See* Order No. 16 (Apr. 30, 2021), *unreviewed by* Comm'n Notice (May 18, 2021). Kappa City failed to show good cause why it should not be held in default for failing to respond to the complaint and notice of investigation. *See id.* These findings satisfy subsections 337(g)(1)(A)–(D). ARK requested a limited exclusion order and a cease and desist order against Kappa City satisfying subsection 337(g)(1)(E). Given that subsections 337(g)(1)(A)–(E) are satisfied, the statute directs the Commission to issue the requested limited exclusion order and cease and desist order, subject to consideration of the public interest. Commissioners Schmidtlein and Karpel find that issuance of the requested relief would not adversely impact the public interest factors.

While temporary remote operating procedures are in place in response to COVID–19, the Office of the Secretary is not able to serve parties that have not retained counsel or otherwise provided a point of contact for electronic service. Accordingly, pursuant to Commission Rules 201.16(a) and 210.7(a)(1) (19 CFR 201.16(a), 210.7(a)(1)), the Commission orders that the complainant complete service for any party/parties without a method of electronic service noted on the attached Certificate of Service and shall file proof of service on the Electronic Document Information System (EDIS).

The Commission vote for this determination took place on July 25, 2022.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: July 25, 2022.

Katherine Hiner,

Acting Secretary to the Commission.

[FR Doc. 2022–16261 Filed 7–28–22; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1020]

Importer of Controlled Substances Application: Usona Institute

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Usona Institute has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 29, 2022. Such persons may also file a written request for a hearing on the application on or before August 29, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal,